Activity Details PDF
	Download Monograph PDF
	Complete Post-Test/ Print CE Certificate

	Faculty
	Statement of Need
	Activity Goal
	Learning Objectives
	Target Audience
	Financial Support
	Credit Information

CMEO Clinical Navigator

Premiere Date: Monday, January 11, 2010

This activity offers CE credit for:

1. Physicians (ACCME/AMA PRA Category 1)
2. Nurses (CNE)
3. Pharmacists (ACPE)

All other clinicians will either receive a CME Attendance Certificate or may choose any of the types of CE credit being offered.
Credit Expiration Date:
Tuesday, January 11, 2011

Faculty

Nasser Hanna, MD  (Editorial Faculty) Associate Professor of Medicine Indiana University School of Medicine Indianapolis, IN

Statement of Need

Non-small cell lung cancer (NSCLC) represents approximately 85% of all lung cancers.(1) Lung cancer represents the most common cancer-related cause of death in men and women. Survival rates for patients with NSCLC are dismal, with fewer than 15% alive at year two and less than 1% alive at year five.(2) Although often considered a preventable disease because of the relationship of lung malignancies to smoking, approximately 10% of cases occur in individuals who have never smoked. Emerging evidence from clinical studies indicates that lung tumors in these patients have been associated with a different phenotype and have a different molecular profile requiring individualized therapy. An increased understanding of the molecular and histologic basis of NSCLC has led to the identification of a number of suitable targets for treatment or chemoprevention of lung cancer. The goal of traditional therapies was to eradicate malignant cells. Emerging molecular therapies target the physiology of cancer and hold promise for better individual and combination therapies for advanced NSCLC to extend survival and preserve an acceptable quality of life. This two-part activity will explore the evolving understanding of NSCLC and report on emerging evidence for targeted, individualized treatment strategies.

---

1. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-1380
2. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158.

Activity Goal

To address knowledge gaps related to the significance of histologic and molecular targets in the development of individualized treatment strategies in patients with NSCLC.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Recognize the significance of histology and molecular traits in treatment selection for patients with lung cancer.
• List epidemiologic and clinical characteristics that differentiate lung cancer in smokers vs. never-smokers.
• Compare and contrast current and emerging therapies in the management of patients with lung cancer and translate that knowledge in to individualized care of patients.

Target Audience

Physicians (surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, epidemiologists), physician assistants, nurse practitioners, nurses, pharmacists, and other healthcare professionals interested in the care of patients with NSCLC.

Financial Support

This activity is supported by an unrestricted educational grant from Pfizer Inc.

Credit Information

CME Credit (Physicians):
Indiana University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Indiana University School of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Note to Physician Assistants: AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA Category I CME credit for the PRA from organizations accredited by ACCME.

CNE Credit (Nurses):
This continuing nursing education activity was approved by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

It has been assigned approval code 7ZPKCL-10. 1.0 contact hours will be awarded upon successful completion.

CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hours (0.1 CEUs)
Universal Program Number: 376-999-10-005-H01-P
Activity Type: knowledge-based

Post-tests, credit request forms, and activity evaluations can be completed online at www.cmeoutfitters.com/test (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required).

This continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC.

CME Outfitters and Indiana University School of Medicine acknowledge medical writer Theodore Bosworth for his primary contribution to the development of this continuing education activity. Mr. Bosworth has no financial relationships to disclose in regard to the products and/or services discussed in this activity.

Disclosure Declaration

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Indiana University School of Medicine (IUSM) and CME Outfitters, LLC, (CMEO) must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in activities sponsored by IUSM and CMEO are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Note: While it offers CME credits, this activity is not intended to provide extensive training or certification in the field.

Dr. Hanna has disclosed that as a member of Data and Safety Monitoring Committee he has received compensation fees from Celgene and Merck.

Unlabeled Use Disclosure

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Indiana University School of Medicine, CME Outfitters, LLC, the faculty, and Pfizer Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

CN-030-011110-02